171 related articles for article (PubMed ID: 22406176)
21. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
22. Th1 development of naive CD4+ T cells is inhibited by co-activation with anti-CD4 monoclonal antibodies.
Goedert S; Germann T; Hoehn P; Koelsch S; Palm N; Rüde E; Schmitt E
J Immunol; 1996 Jul; 157(2):566-73. PubMed ID: 8752903
[TBL] [Abstract][Full Text] [Related]
23. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway.
Shibasaki S; Yamashita K; Goto R; Wakayama K; Tsunetoshi Y; Zaitsu M; Igarashi R; Haga S; Ozaki M; Umezawa K; Todo S
Transplantation; 2013 Feb; 95(4):542-50. PubMed ID: 23269193
[TBL] [Abstract][Full Text] [Related]
24. A combination of anergic cells' adoptive transfer and rapamycin therapy prolongs cardiac allograft survival in mice.
Cai Y; Tang XD; Zhou PJ
Scand J Immunol; 2005 Mar; 61(3):266-73. PubMed ID: 15787744
[TBL] [Abstract][Full Text] [Related]
25. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation.
de Waal Malefyt R; Yssel H; de Vries JE
J Immunol; 1993 Jun; 150(11):4754-65. PubMed ID: 7684412
[TBL] [Abstract][Full Text] [Related]
26. Type 2 immune deviation has differential effects on alloreactive CD4+ and CD8+ T cells.
Matesic D; Valujskikh A; Pearlman E; Higgins AW; Gilliam AC; Heeger PS
J Immunol; 1998 Nov; 161(10):5236-44. PubMed ID: 9820495
[TBL] [Abstract][Full Text] [Related]
27. Determination of the functional status of alloreactive T cells by interferon-gamma kinetics.
Kwun J; Knechtle SJ; Hu H
Transplantation; 2006 Feb; 81(4):590-8. PubMed ID: 16495808
[TBL] [Abstract][Full Text] [Related]
28. Suppressive effect of a novel water-soluble artemisinin derivative SM905 on T cell activation and proliferation in vitro and in vivo.
Wang JX; Tang W; Yang ZS; Wan J; Shi LP; Zhang Y; Zhou R; Ni J; Hou LF; Zhou Y; He PL; Yang YF; Li Y; Zuo JP
Eur J Pharmacol; 2007 Jun; 564(1-3):211-8. PubMed ID: 17349993
[TBL] [Abstract][Full Text] [Related]
29. Cyclosporine combined with nonlytic interleukin 2/Fc fusion protein improves immune response to hepatitis B vaccination in a mouse skin transplantation model.
Li Z; Zhang D; Gao J; Li WX; Zhu JY
Transplant Proc; 2013; 45(6):2559-64. PubMed ID: 23953581
[TBL] [Abstract][Full Text] [Related]
30. Kinetics of ex-vivo cytokine production by splenocytes during murine acquired immunodeficiency syndrome (MAIDS).
Akarid K; Pocidalo MA; Desforges B; Sinet M
Eur Cytokine Netw; 1995; 6(3):181-5. PubMed ID: 8589275
[TBL] [Abstract][Full Text] [Related]
31. Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection.
He F; Chen Z; Xu S; Cai M; Wu M; Li H; Chen X
Surgery; 2009 Jun; 145(6):663-74. PubMed ID: 19486771
[TBL] [Abstract][Full Text] [Related]
32. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production.
Yoshimoto T; Takeda K; Tanaka T; Ohkusu K; Kashiwamura S; Okamura H; Akira S; Nakanishi K
J Immunol; 1998 Oct; 161(7):3400-7. PubMed ID: 9759857
[TBL] [Abstract][Full Text] [Related]
33. Anti-CCL25 antibody prolongs skin allograft survival by blocking CCR9 expression and impairing splenic T-cell function.
Li J; Xiong T; Xiao R; Xiong A; Chen J; Altaf E; Zheng Y; Zhu G; He Y; Tan J
Arch Immunol Ther Exp (Warsz); 2013 Jun; 61(3):237-44. PubMed ID: 23456208
[TBL] [Abstract][Full Text] [Related]
34. A tolerogenic semimature dendritic cells induce effector T-cell hyporesponsiveness by activation of antigen-specific CD4+CD25+ T regulatory cells that promotes skin allograft survival in mice.
Fu BM; He XS; Yu S; Hu AB; Zhang J; Ma Y; Tam NL; Huang JF
Cell Immunol; 2010; 261(1):69-76. PubMed ID: 20038461
[TBL] [Abstract][Full Text] [Related]
35. Induction of regulatory T cells and prolongation of survival of fully allogeneic cardiac grafts by administration of Tokishakuyaku-san in mice.
Zhang Q; Uchiyama M; Jin X; Iwami D; Shirasugi N; Watanabe T; Niimi M
Surgery; 2011 Nov; 150(5):923-33. PubMed ID: 21943639
[TBL] [Abstract][Full Text] [Related]
36. Activated allogeneic NK cells as suppressors of alloreactive responses.
Hu B; He Y; Wu Y; Bao G; Liu H; Welniak LA; Murphy WJ
Biol Blood Marrow Transplant; 2010 Jun; 16(6):772-81. PubMed ID: 20197103
[TBL] [Abstract][Full Text] [Related]
37. Colchicine-derived compound CT20126 promotes skin allograft survival by regulating the balance of Th1 and Th2 cytokine production.
Lee SJ; Namkoong S; Ha KS; Nam WD; Kwon YG; Lee H; Yoon EY; Chang DJ; Kim SO; Kim YM
Exp Mol Med; 2007 Apr; 39(2):230-8. PubMed ID: 17464185
[TBL] [Abstract][Full Text] [Related]
38. A combination of donor specific transfusion and rapamycin prolongs cardiac allograft survival in mice.
Wu K; Xiang F; Yuan J; Zeng Z; Zhou H; Chang S; Chen ZK
Transplant Proc; 2008 Dec; 40(10):3699-701. PubMed ID: 19100468
[TBL] [Abstract][Full Text] [Related]
39. J2 prolongs the corneal allograft survival through inhibition of the CD4+ T cell-mediated response in vivo.
Xiao H; Zhang H; Yu ZY; Zhang L; Yu M; Huang YF; Li S; Shen BF; Li Y
Transpl Immunol; 2007 Nov; 18(2):130-7. PubMed ID: 18005857
[TBL] [Abstract][Full Text] [Related]
40. (5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide analog mediates immunosuppressive effects in vitro and in vivo.
Zhou R; Zhang F; He PL; Zhou WL; Wu QL; Xu JY; Zhou Y; Tang W; Li XY; Yang YF; Li YC; Zuo JP
Int Immunopharmacol; 2005 Dec; 5(13-14):1895-903. PubMed ID: 16275624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
